Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
87.4M
-
Number of holders
-
91
-
Total 13F shares, excl. options
-
61.3M
-
Shares change
-
+3.87M
-
Total reported value, excl. options
-
$308M
-
Value change
-
+$7.25M
-
Put/Call ratio
-
0.14
-
Number of buys
-
41
-
Number of sells
-
-58
-
Price
-
$5.03
Significant Holders of Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TERN) as of Q3 2023
121 filings reported holding TERN - Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share as of Q3 2023.
Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TERN) has 91 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 61.3M shares
of 87.4M outstanding shares and own 70.15% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (7.62M shares), Vivo Capital, LLC (6.66M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (6.04M shares), Deep Track Capital, LP (6M shares), FMR LLC (5.12M shares), BlackRock Inc. (3.16M shares), VR Adviser, LLC (3.09M shares), BRAIDWELL LP (2.84M shares), VANGUARD GROUP INC (2.2M shares), and FRANKLIN RESOURCES INC (2.15M shares).
This table shows the top 91 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.